Skip to main
TMCI

TMCI Stock Forecast & Price Target

TMCI Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 20%
Buy 0%
Hold 60%
Sell 20%
Strong Sell 0%

Bulls say

Treace Medical Concepts is facing short-term challenges due to lower bunion surgery volumes, a shift towards less complex MIS products, and increased competition in the market. While the company has a strong product portfolio, it will take time for them to stabilize and regain market share. TMCI's valuation and growth prospects may be impacted in the near term, but the long-term potential remains strong in the bunion surgery market.

Bears say

Treace Medical Concepts is a company that has had multiple guidance resets over the past 2 years and is currently facing significant headwinds in their core business, with the possibility of negative growth in 2026. This has led to a decrease in price targets and a continued multiple discount compared to peers. Even with new product launches and pipeline innovations, there is uncertainty about when the company will be able to return to positive growth in an increasingly competitive market. In addition, increased competition, declining demand for elective foot surgery, and pressure on average selling prices are all factors that could hinder the company's ability to improve its financials and stock performance in the near term.

TMCI has been analyzed by 5 analysts, with a consensus rating of Hold. 20% of analysts recommend a Strong Buy, 0% recommend Buy, 60% suggest Holding, 20% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Treace Medical Concepts and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Treace Medical Concepts (TMCI) Forecast

Analysts have given TMCI a Hold based on their latest research and market trends.

According to 5 analysts, TMCI has a Hold consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Treace Medical Concepts (TMCI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.